Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September…
Results for the Quarter Ended March 31, 2025 and Other Recent Highlights: Net investment income per share for the quarter was…
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines…
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…
FORT WORTH, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced…
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time…
Operating results in line with expectationsReiterating previously issued full-year 2025 guidanceCompleted spin-off of Resolute Holdings Management, Inc. (Nasdaq: RHLD)Accounting standards…
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data…
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company…
Commissioning of Louisiana hydrogen plant, global electrolyzer momentum, and improved cash flow positions Plug for continued commercial growthSLINGERLANDS, N.Y., May…
This website uses cookies.